Nedocromil (Tilade) and sodium cromoglicate (Intal Forte) inhaler discontinuation
Tilade and Intal Forte inhalers are mast cell stabilisers primarily used for the preventative treatment of asthma.
On this page:
- Information for patients
- Information for prescribers
- Information for pharmacists
Sanofi, the supplier of nedocromil and sodium cromoglicate inhalers, is discontinuing its Tilade and Intal Forte inhalers in New Zealand.
Nedocromil and sodium cromoglicate inhalers will no longer be available once the current supply runs out.
- Supply of Tilade inhalers is likely to run out by late November 2020.
- Supply of Intal Forte inhalers is likely to run out by March 2021.
You will need to talk to your prescriber about other medicines to help you control your asthma.
There are no other funded nedocromil or sodium cromoglicate inhalers. However there are a number of other funded preventer inhalers you could switch to. Your prescriber can advise you on what treatments will work best for you.
We know that changing medications can be a hassle and we're sorry for any inconvenience this causes.
You will need to:
- ensure no new patients are started on Tilade or Intal Forte inhalers
- transition patients currently on Tilade or Intal Forte inhalers to alternative treatments.
From 1 July 2020, sodium cromoglicate and nedocromil inhalers will not be funded for new patients.
We have received advice from the Respiratory Subcommittee of the Pharmacology and Therapeutics Advisory Committee (one of our expert clinical advisory groups). They advise that patients can be managed on alternative treatments, in line with current asthma guidelines. These treatments include:
- inhaled corticosteroids
- inhaled corticosteroid and long-acting beta-adrenoceptor agonist combinations
- P.R.N short-acting beta-adrenoceptor agonists.
This information is for health professionals and summarises the clinical advice we received on possible alternatives to Tilade and Intal Forte inhalers.
PHARMAC cannot give clinical advice to individuals. This information is a guide only.
The Asthma and Respiratory Foundation NZ Adult Asthma Guidelines are a useful tool for health professionals to use when reviewing an individual’s asthma care.
BpacNZ has published information on managing adults with asthma in primary care which may be useful.
Stock of the:
- Tilade inhaler is expected to be exhausted by late November 2020.
- Intal Forte inhaler is expected to be exhausted by March 2021.
There are no other funded nedocromil or sodium cromoglicate inhalers.
Subsidy for existing patients only from 1 July 2020
From 1 July 2020, sodium cromoglicate and nedocromil will only be subsidised for patients who were taking that medicine before 1 July 2020.
Pharmacists will need to annotate the prescription as endorsed where a record of prior dispensing exists.
Note: A “subsidy by endorsement” should not apply to:
- Rexacrom eye drops (2%) (pharmacode 2224291)
- Nalcrom capsules (100mg) (pharmacode 259349)
The subsidy by endorsement was added in error to these two items when the endorsement was correctly added to the Intal Forte inhaler (pharmacode 2422743).
We will fix this error in the 1 August 2020 Schedule.
In the meantime, please annotate the prescription as “endorsed” for patients who are being dispensed either the eye drops or the capsules, even if there is no record of prior dispensing.
Delisting from the Pharmaceutical Schedule
Tilade will be delisted from 1 February 2021
Intal Forte will be delisted from 1 May 2021.
Last updated: 23 September 2020